Caribou Biosciences, Inc. 8K

Caribou Biosciences reported Q2 2026 results, showcased positive clinical progress for vispa-cel and CB-011, detailed plans for a pivotal phase 3 trial, and updated its cash runway expectation through 2027.

On August 13, 2026, Caribou Biosciences, Inc. reported its second quarter 2026 financial results and provided a business update, highlighting encouraging clinical data for its allogeneic CAR-T programs vispacabtagene regedleucel (vispa-cel) and CB-011 presented at the 2026 European Hematology Association meeting, including strong response rates, durable efficacy, and manageable safety profiles in second-line large B cell lymphoma and relapsed/refractory multiple myeloma. The company outlined plans for the ANTLER-3 pivotal phase 3 trial in CD19-naïve second-line LBCL patients and ongoing dose expansion in the CaMMouflage phase 1 trial, while reporting reduced R&D and G&A expenses, a narrowed GAAP net loss of $24.3 million for the quarter, and cash, cash equivalents, and marketable securities of $113.8 million as of June 30, 2026, which it expects will fund operations, including CB-011 dose expansion and ANTLER-3 start-up activities, through the end of 2027 as it explores additional funding options.

Filing Facts

CIK

1619856

Ticker

-

Form

8K

Source Type

sec

Accession

0001619856-26-000053

Alert Tier

6